PortalPublikationenDonor Lymphocyte Infusions for Chronic Myeloid Leukemia Rela...

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?

Standard

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? / Radujkovic, Aleksandar; Guglielmi, Cesare; Bergantini, Stefania; Iacobelli, Simona; van Biezen, Anja; Milojkovic, Dragana; Gratwohl, Alois; Schattenberg, Antonius V M B; Verdonck, Leo F; Niederwieser, Dietger W; de Witte, T; Kröger, Nicolaus; Olavarria, Eduardo; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

in: BIOL BLOOD MARROW TR, Jahrgang 21, Nr. 7, 19.03.2015, S. 1230-1236.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Radujkovic, A, Guglielmi, C, Bergantini, S, Iacobelli, S, van Biezen, A, Milojkovic, D, Gratwohl, A, Schattenberg, AVMB, Verdonck, LF, Niederwieser, DW, de Witte, T, Kröger, N, Olavarria, E & Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT) 2015, 'Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?', BIOL BLOOD MARROW TR, Jg. 21, Nr. 7, S. 1230-1236. https://doi.org/10.1016/j.bbmt.2015.03.012

APA

Radujkovic, A., Guglielmi, C., Bergantini, S., Iacobelli, S., van Biezen, A., Milojkovic, D., Gratwohl, A., Schattenberg, A. V. M. B., Verdonck, L. F., Niederwieser, D. W., de Witte, T., Kröger, N., Olavarria, E., & Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2015). Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? BIOL BLOOD MARROW TR, 21(7), 1230-1236. https://doi.org/10.1016/j.bbmt.2015.03.012

Vancouver

Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D et al. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? BIOL BLOOD MARROW TR. 2015 Mär 19;21(7):1230-1236. https://doi.org/10.1016/j.bbmt.2015.03.012

Bibtex

@article{da3639ea22e24e41ab47da15df9a7618,
title = "Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?",
abstract = "Donor lymphocyte infusions (DLI) are an effective treatment for relapsed chronic myeloid leukemia (CML) after allogeneic stem cell transplantation (alloSCT). Leukemia resistance and secondary graft-versus-host disease (GVHD) are major obstacles to success with DLI. The aim of this study was to identify pre-DLI factors associated with prolonged survival in remission without secondary GVHD. We retrospectively analyzed 500 patients treated with DLI for CML relapse (16% molecular, 30% cytogenetic, and 54% hematological) after alloSCT. The overall probabilities of failure- and secondary GVHD-free survival (FGFS) were 29% and 27% at 5 and 10 years after DLI, respectively. The type of relapse was the major factor influencing FGFS (40% for molecular and/or cytogenetic relapse and 20% for hematological relapse at 5 years, P < .001). Chronic GVHD before DLI and an interval <1 year between alloSCT and first DLI were independently associated with inferior FGFS in patients with molecular and/or cytogenetic relapse. Consequently, FGFS was 13%, 35%, to 56% at 5 years in patients with 2, 1, and 0 adverse features, respectively. In patients with hematological relapse, independent adverse prognostic factors for FGFS were initial dose of CD3(+) cells ≥ 50 × 10(6)/kg, donor-recipient sex mismatch, and chronic GVHD before DLI. FGFS was 0%, 17%, 33%, to 37% in patients with 3, 2, 1, and 0 adverse features, respectively. The probability of survival in remission without secondary GVHD was highest (>50% at 5 years) when DLI were given beyond 1 year from alloSCT for molecular and/or cytogenetic CML relapse that was not preceded by chronic GVHD.",
author = "Aleksandar Radujkovic and Cesare Guglielmi and Stefania Bergantini and Simona Iacobelli and {van Biezen}, Anja and Dragana Milojkovic and Alois Gratwohl and Schattenberg, {Antonius V M B} and Verdonck, {Leo F} and Niederwieser, {Dietger W} and {de Witte}, T and Nicolaus Kr{\"o}ger and Eduardo Olavarria and {Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)}",
note = "Copyright {\textcopyright} 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.",
year = "2015",
month = mar,
day = "19",
doi = "10.1016/j.bbmt.2015.03.012",
language = "English",
volume = "21",
pages = "1230--1236",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

RIS

TY - JOUR

T1 - Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?

AU - Radujkovic, Aleksandar

AU - Guglielmi, Cesare

AU - Bergantini, Stefania

AU - Iacobelli, Simona

AU - van Biezen, Anja

AU - Milojkovic, Dragana

AU - Gratwohl, Alois

AU - Schattenberg, Antonius V M B

AU - Verdonck, Leo F

AU - Niederwieser, Dietger W

AU - de Witte, T

AU - Kröger, Nicolaus

AU - Olavarria, Eduardo

AU - Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

N1 - Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

PY - 2015/3/19

Y1 - 2015/3/19

N2 - Donor lymphocyte infusions (DLI) are an effective treatment for relapsed chronic myeloid leukemia (CML) after allogeneic stem cell transplantation (alloSCT). Leukemia resistance and secondary graft-versus-host disease (GVHD) are major obstacles to success with DLI. The aim of this study was to identify pre-DLI factors associated with prolonged survival in remission without secondary GVHD. We retrospectively analyzed 500 patients treated with DLI for CML relapse (16% molecular, 30% cytogenetic, and 54% hematological) after alloSCT. The overall probabilities of failure- and secondary GVHD-free survival (FGFS) were 29% and 27% at 5 and 10 years after DLI, respectively. The type of relapse was the major factor influencing FGFS (40% for molecular and/or cytogenetic relapse and 20% for hematological relapse at 5 years, P < .001). Chronic GVHD before DLI and an interval <1 year between alloSCT and first DLI were independently associated with inferior FGFS in patients with molecular and/or cytogenetic relapse. Consequently, FGFS was 13%, 35%, to 56% at 5 years in patients with 2, 1, and 0 adverse features, respectively. In patients with hematological relapse, independent adverse prognostic factors for FGFS were initial dose of CD3(+) cells ≥ 50 × 10(6)/kg, donor-recipient sex mismatch, and chronic GVHD before DLI. FGFS was 0%, 17%, 33%, to 37% in patients with 3, 2, 1, and 0 adverse features, respectively. The probability of survival in remission without secondary GVHD was highest (>50% at 5 years) when DLI were given beyond 1 year from alloSCT for molecular and/or cytogenetic CML relapse that was not preceded by chronic GVHD.

AB - Donor lymphocyte infusions (DLI) are an effective treatment for relapsed chronic myeloid leukemia (CML) after allogeneic stem cell transplantation (alloSCT). Leukemia resistance and secondary graft-versus-host disease (GVHD) are major obstacles to success with DLI. The aim of this study was to identify pre-DLI factors associated with prolonged survival in remission without secondary GVHD. We retrospectively analyzed 500 patients treated with DLI for CML relapse (16% molecular, 30% cytogenetic, and 54% hematological) after alloSCT. The overall probabilities of failure- and secondary GVHD-free survival (FGFS) were 29% and 27% at 5 and 10 years after DLI, respectively. The type of relapse was the major factor influencing FGFS (40% for molecular and/or cytogenetic relapse and 20% for hematological relapse at 5 years, P < .001). Chronic GVHD before DLI and an interval <1 year between alloSCT and first DLI were independently associated with inferior FGFS in patients with molecular and/or cytogenetic relapse. Consequently, FGFS was 13%, 35%, to 56% at 5 years in patients with 2, 1, and 0 adverse features, respectively. In patients with hematological relapse, independent adverse prognostic factors for FGFS were initial dose of CD3(+) cells ≥ 50 × 10(6)/kg, donor-recipient sex mismatch, and chronic GVHD before DLI. FGFS was 0%, 17%, 33%, to 37% in patients with 3, 2, 1, and 0 adverse features, respectively. The probability of survival in remission without secondary GVHD was highest (>50% at 5 years) when DLI were given beyond 1 year from alloSCT for molecular and/or cytogenetic CML relapse that was not preceded by chronic GVHD.

U2 - 10.1016/j.bbmt.2015.03.012

DO - 10.1016/j.bbmt.2015.03.012

M3 - SCORING: Journal article

C2 - 25797175

VL - 21

SP - 1230

EP - 1236

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 7

ER -